If there is one practical step in this whole cluster, it is this: involve a qualified clinician, and disclose fully. The considerations that matter most — medications, psychiatric and cardiac history, other conditions — are precisely the ones a professional can assess and a website cannot. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y Disclose all medications and supplements, any psychiatric or family psychiatric history, and cardiac conditions, because a clinician can only weigh risk accurately with a complete picture. [2] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 This is not a substitute for medical advice, and involving a clinician is part of understanding the topic — not a commitment to proceed.
Not medical advice. Involve a qualified clinician for any personal health decision. This explains why and what to disclose; it does not assess your case.
Understanding, not a plan. Having this conversation is responsible orientation, not a step toward beginning.
Why a clinician, and why early
General information has a hard limit: it cannot see your health picture. Your medications, your psychiatric and cardiac history, and your other conditions are what most change the risk calculus, and those are clinical questions. Bringing a clinician in early — while you are still understanding the topic — means any eventual decision rests on your actual situation rather than on averages, which is the core of harm reduction. [3] Peer-reviewed Drug harms in the UK: a multicriteria decision analysis doi:10.1016/S0140-6736(10)61462-6
What to disclose
Full disclosure is the whole point; partial disclosure defeats it.
| Disclose | Why it matters |
|---|---|
| All medications and supplements | Interactions with psilocybin are documented and some are serious |
| Psychiatric history (incl. family) | History of psychosis or bipolar disorder changes the risk picture |
| Cardiac conditions | Cardiovascular factors are part of physiological safety |
| Seizure history | Neurologic risk and medication context |
| Alcohol and other substance use | Stimulants, sedatives, and other psychoactives change risk |
| Other significant conditions | They may alter contraindications and overall risk |
The literature on interactions between psychiatric medications and psilocybin is detailed enough to make clear why the medication list is not optional. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y Interactions covers psychiatric medications specifically, and Safety covers contraindications — read these so the conversation is an informed one.
If the response is disapproval or unfamiliarity
A clinician who disapproves is still telling you something about risk; one unfamiliar with microdosing can still assess your medications, history, and contraindications, which is the part that matters most. The aim is an honest professional read on your health context, not a sign-off.
A clinician is for understanding, not gatekeeping
Having this conversation does not commit you to anything. You can speak to a clinician purely to understand your own risk picture and still decide against proceeding — a decision that is simply better for being informed. Population-level reassurance about psychedelics and mental health does not replace this individual assessment. [4] Observational Psychedelics not linked to mental health problems or suicidal behavior: A population study doi:10.1177/0269881114568039
A conversation, not a permission slip
The point of a clinician conversation is not to obtain approval from a website, or to make a clinician endorse microdosing; it is to ensure that relevant medical, psychiatric, cardiac, and medication factors are not hidden from the risk discussion. If a clinician is unfamiliar with the research, the safest response is not to bypass the conversation but to focus on the known medical facts — medications, psychiatric and cardiac history, and risk categories — which is the part that matters most.
- Full disclosure
- Accurate risk assessment depends on a complete picture. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
- Clinician over website
- Personal health questions need a professional, not general information.
- Harm reduction
- Involving a clinician early is the responsible default. [3] Peer-reviewed Drug harms in the UK: a multicriteria decision analysis doi:10.1016/S0140-6736(10)61462-6
- Not a commitment
- The conversation is for understanding, and a decision not to proceed is valid.
Frequently asked questions
Why should a clinician be involved at all if I am only considering it?
Because the considerations that matter most — your medications, your psychiatric and cardiac history, your other conditions — are exactly the ones a clinician is trained to assess and a website cannot. Involving a clinician early, while you are still understanding the topic, means any decision is informed by your actual health picture rather than by general information. It is the difference between an informed decision and a guess, and it applies whether you ultimately proceed or not.
What should I disclose?
The honest answer is everything relevant: all medications and supplements, any psychiatric history including a family history of psychosis or bipolar disorder, any cardiac conditions, and other significant medical conditions. Interactions between psychiatric medications and psilocybin are documented in the literature, [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y and some conditions change the risk picture substantially. A clinician can only assess risk accurately with a complete picture, so partial disclosure undermines the entire point of the conversation.
What if my doctor disapproves or does not know much about it?
Both are common and neither is a reason to withhold information. A clinician who disapproves is still giving you a data point about risk worth understanding; a clinician unfamiliar with the topic can still assess your medications, history, and contraindications, which is the part that matters most. If needed, you can seek a clinician with relevant knowledge, but the goal is an honest professional assessment of your health context, not approval.
Is this conversation a substitute for reading the safety material?
No — they complement each other. The safety and interactions material helps you understand what to ask and why it matters, and a clinician applies that to your individual situation. Reading first means you can have a more informed conversation; the conversation then personalises what the general material cannot. Neither replaces the other, and neither replaces a qualified clinician’s judgment about your specific case.
Does involving a clinician mean I am planning to microdose?
No. Talking to a clinician is part of understanding the topic responsibly, not a commitment to anything. You can have the conversation purely to understand your own risk picture and still decide against proceeding — and that decision is better for having been informed by a professional. Framing the clinician as a source of understanding rather than a gatekeeper to a plan keeps the focus where it belongs.